Lancet HIV

Article	Citations
Transplant donation without discrimination	234
How do we prevent anal cancer in people living with HIV?	205
Argentina updates HIV laws	138
Evidence supports use of on-demand PrEP for HIV prevention	136
How much could long-acting PrEP cost in South Africa?	133
Correction to Lancet HIV 2022; 9: e791–800	132
The Australian AIDS crisis through the eyes of volunteers	132
HIV and COVID-19: juxtaposition of two pandemics	130
Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia	103
Optimising anal cancer screening through risk stratification	99
Lung cancer in people living with HIV	96
Controversial chronicler of LGBTQ rights	95
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	95
Scaling up access to HIV pre-exposure prophylaxis (PrEP): should nurses do the job?	85
Steps toward quick and equitable roll-out of lenacapavir	83
Are we ready for long-acting HIV treatment for adolescents?	81
Risk estimation in HIV reveals our usual blind spots	81
Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised c	76
Safety, tolerability, and pharmacokinetics of an annual tenofovir alafenamide silicone subdermal implant in South African women: a two-part, randomised, placebo-controlled, double-blind, first-in-huma	74
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial	71
Lenacapavir: an attractive option, but proceed with caution	70
All roads lead to Westminster: the infected blood scandal	69
Redefining care: injectable HIV treatment for adolescents	69
Unheard testimony	63
Gains and gaps: addressing HIV in diverse sex worker groups	61

Fate of people with HIV in jeopardy in Ukraine	58
Stigma reduction is key to improving the HIV care continuum	55
Game-changing study of second-line HIV treatment	52
Integration of sexual health and HIV services	51
Reducing HIV transmission in British Columbia, Canada	51
Recent gay Black history in the UK	50
Suicide prevention research is crucial to achieving health equity for people with HIV	49
Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor ther	46
Outcomes of people living with HIV after hospital discharge: a systematic review and meta-analysis	46
HIV care cascade and associated factors among men who have sex with men, transgender women, and genderqueer individuals in Zimbabwe: findings from a biobehavioural survey using respondent-driven sampl	43
The contribution of intimate partner violence to vertical HIV transmission: a modelling analysis of 46 African countries	43
Equitable access to long-acting PrEP on the way?	43
Sex as a biological variable in HIV-1 and schistosome co-infection	42
More evidence for worse COVID-19 outcomes in people with HIV	42
Making America unhealthy again	41
Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E–4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial	40
HIV treatment-as-prevention and its effect on incidence of HIV among cisgender gay, bisexual, and other men who have sex with men in Australia: a 10-year longitudinal cohort study	40
A public health approach to drug use crucial to ending AIDS	40
Lateral flow assay-based CD4 cell count testing for advanced HIV disease	39
Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study	38
Healing the stigma of HIV/AIDS	37
Connie Norman: a warm tribute to a forgotten AIDS activist	37
Eliminating HIV in the UK among men who have sex with men	35
Patterns of post-partum HIV care engagement	35
PEPFAR: promises and pitfalls	34
HIV self-testing: from availability to strategic deployment	34
An eventful conference	34
Reduction in mortality from HIV-related CNS infections in routine care in Africa (DREAMM): a before-and-after, implementation study	34
HIV incidence and impact of interventions among female sex workers and their clients in the Middle East and north Africa: a modelling study	34
Use of WHO paediatric weight-band dosing in drug labels	34
Living with COVID-19 and preparing for future pandemics: revisiting lessons from the HIV pandemic	32
Lifestyle modification programme for people living with HIV with metabolic dysfunction-associated steatotic liver disease: a randomised controlled trial	32
Improving health equity and ending the HIV epidemic in the USA: a distributional cost-effectiveness analysis in six cities	32
Preventing sexually transmitted infections in the age of PrEP	32
Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B	31
Lesotho's progress towards UNAIDS 95-95-95 targets from 2016 to 2020: comparison of Population-based HIV Impact Assessments	31
Moving beyond hotspots of HIV prevalence to geospatial hotspots of UNAIDS 95-95-95 targets in sub-Saharan Africa	31
How can Africa sustain its HIV response amid US aid cuts?	31
Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and th	30
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial	30
Trends in HIV testing, the treatment cascade, and HIV incidence among men who have sex with men in Africa: a systematic review and meta-analysis	29
Advancing the prevention and treatment of HIV in children: priorities for research and development	28
Reduction of HIV reservoir after stem cell transplantation	27
HIV-free generation within reach for Botswana	27
Addressing partner violence to end infant HIV infection	26
Thank you to The Lancet HIV's statistical and peer reviewers in 2023	26
Intersectional climate justice, health equity, and HIV	26
Can treatment-as-prevention and PrEP reduce HIV incidence?	26
Coffee with IAS President Beatriz Grinsztejn	25
Implementation of PrEP in Latin America	25

Closing the gap to UNAIDS 95-95-95: Lesotho's success story	25
Highlights from the 25th International AIDS Conference	25
Second-line HIV treatments for adults in LMICs	25
Effects of self-testing on HIV outcomes in west Africa	25
Estimates of the prevalence of undiagnosed HIV among children living with HIV in Eswatini, Lesotho, Malawi, Namibia, Tanzania, Zambia, and Zimbabwe from 2015 to 2017: an analysis of data from the cros	24
Crucial need for improved pharmacovigilance in pregnancy	24
No woman left behind: achieving cervical cancer elimination among women living with HIV	24
Effects of clinical, comorbid, and social determinants of health on brain ageing in people with and without HIV: a retrospective case-control study	24
Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa	23
Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label,	23
The HIV care continuum for sexually active transgender women in three metropolitan municipalities in South Africa: findings from a biobehavioural survey 2018–19	23
Pharmacokinetics and safety of dolutegravir in children receiving rifampicin tuberculosis treatment in South Africa (ORCHID): a prospective cohort study	22
Post-exposure prophylaxis to prevent HIV: new drugs, new approaches, and more questions	22
A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial	22
Metabolic implications and safety of dolutegravir use in pregnancy	22
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study	21
Treatment of HIV and HBV coinfection	21
The HIV vaccine quest: ethical and implementation challenges	21
Can COVID-19 changes reduce stigma in African HIV clinics?	21
Need for clear inclusion criteria in reviews of antiretroviral treatments	21
Breast cancer survival in women living with HIV	21
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	20
The future of HIV pre-exposure prophylaxis adherence: reducing barriers and increasing opportunities	20
Complex response to HIV and tuberculosis in South Sudan	20
Point-of-care testing to achieve paediatric 95-95-95 targets	20
Incorporating oral PrEP into standard prevention services for South African women: a nested interrupted time-series study	19
Adolescent retention in HIV care within differentiated service-delivery models in sub-Saharan Africa	19
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex w	18
Making PrEP easy	18
Dolutegravir drug-resistance monitoring in Africa	18
Identifying risk factors for anal cancer in people with HIV in Spain: a multicentre retrospective cohort study nested in the PISCIS cohort	17
Thank you to The Lancet HIV's clinical and statistical peer reviewers in 2021	17
HERO—providing support for those engaged in chemsex	17
Realising long-acting ART as first-line treatment	17
Trends in suicide mortality among people with HIV after diagnosis during 2012–18: a retrospective, national cohort study in China	17
Integrase inhibitors hand us a new HIV clinical puzzle	17
Paying tribute to a generation devastated by HIV/AIDS	17
Activists step in to deliver PEP and PrEP in Mexico	16
Long-acting PrEP for adolescent girls and young women	16
Critical illness due to infection in people living with HIV	16
HIV treatment in Russia on the brink of crisis	16
Epidemiology of severe COVID-19 from South Africa	16
Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis	15
Unified health surveys for integrated health systems	15
Initiation and continued use of oral pre-exposure prophylaxis among pregnant and postpartum women in South Africa (PrEP-PP): a demonstration cohort study	15
Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study	15
Non-communicable diseases in older people living with HIV in four African countries: a cohort study	15
Inherited fear: 40 years of HIV/AIDS in the UK	14
A new index to guide global drug policies	14
Zvandiri—when medicines alone are not enough	14
Ending HIV in Chicago by 2030	14
Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008–20: a national cohort study	14
HIV-related CNS infections: translating DREAMM into reality	14
Improving outcomes for children in families with HIV	14
Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study	14
A career dedicated to public service	13
PEPFAR reauthorisation hangs in the balance	13
Increased risk of mental illness in people with HIV	13
Expanding options of child-friendly, single-tablet regimens for young children with HIV	13
Correction to Lancet HIV 2023; 10: e424–26	13
Tajikistan faces a crucial moment in HIV/AIDS response	13
Expanding PrEP treatment options with a potent anti-HIV antibody	13
Forgiveness of an intermittent HIV treatment strategy	13
Reimagining HIV prevention with artificial intelligence	13
Correction to Lancet HIV 2025; 12: e473–84	13
HIV incidence estimation among female sex workers in South Africa: a multiple methods analysis of cross-sectional survey data	12
Outdated attitudes to HIV must change	12
Thank you to The Lancet HIV's statistical and peer reviewers in 2022	12
HIV viral suppression is key to healthy longevity	12
Trauma-informed HIV prevention for forcibly displaced adolescents and young adults	12
Equitable access to PrEP is essential to reap its benefits	12
Home delivery of ART: could this be a reality in South Africa?	12
Immunological and virological findings in a patient with exceptional post-treatment control: a case report	12
Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration	12
Long-acting PrEP: new opportunities with some drawbacks	12
Response to Thailand's commitment to support community-led HIV services	12
UK and US militaries update HIV policies	11
COVID-19 antivirals must not affect HIV drug supply	11
Where does doravirine fit in current antiretroviral therapy?	11
Potential population-level effects of HIV self-test distribution among key populations in Côte d'Ivoire, Mali, and Senegal: a mathematical modelling analysis	11

Real-world safety of pre-exposure prophylaxis for HIV	11
Screening for chlamydia and incidence of symptomatic infections	11
What future for HIV vaccines?	11
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial	10
Projected outcomes of universal testing and treatment in a generalised HIV epidemic in Zambia and South Africa (the HPTN 071 [PopART] trial): a modelling study	10
Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004–18: a cohort study	10
Putting people first in communication about HIV	10
Mexican perspective on the Mosaico HIV vaccine trial	10
Reassessing oral lead-in for injectable long-acting HIV therapy	10
Defining principles for a choice-based approach to HIV prevention	10
Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies	10
Paediatric abacavir–lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharm	10
Expansion of PrEP and PEP services in China	10
Ending AIDS as a public health threat: the imperative for clear messaging on U=U, viral suppression, and zero risk	10
The urgent need for opioid agonist treatment in Russia	9
Legislation threat to services for LGBTQ+ people in Georgia	9
Effectiveness of bi-monthly long-acting injectable cabotegravir and rilpivirine as maintenance treatment for HIV-1 in the Netherlands: results from the Dutch ATHENA national observational cohort	9
It is time to act on ageing	9
So many harms, so little benefit: a global review of the history and harms of HIV criminalisation	9
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-	9
Documenting Brazil's battle with HIV/AIDS	9
Low-cost point-of-care urine test to enhance PrEP adherence	9
COP27 Climate Change Conference: urgent action needed for Africa and the world	9
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of	8
Acceptability, feasibility, and effectiveness of caregiver-assisted HIV self-testing among children using an oral mucosal test in Uganda and Zambia: a prospective interventional study	8
Dolutegravir dosing with rifampicin	8
A community-based child health and parenting intervention to improve child HIV testing, health, and development in rural Lesotho (Early Morning Star): a cluster-randomised, controlled trial	8
Do we need routine integrase resistance testing before starting antiretroviral therapy?	8
CD4 cell counts at HIV diagnosis in the Eastern Mediterranean Region	8
Association of life-course events with predictors of HIV risk behaviour and HIV acquisition in Manicaland, Zimbabwe: a longitudinal analysis of a population cohort	8
Mental health needs of adolescents with HIV in Africa	8
Longitudinal evolution of the HIV effective reproduction number following sequential expansion of treatment as prevention and pre-exposure prophylaxis in British Columbia, Canada: a population-level p	8
Use of mobile phone data in HIV epidemic control	8
Social media helping younger adults combat HIV stigma	7
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial	7
Addressing the evidence gap for HIV prevention in pregnancy	7
Viral view: 100 years of transmission	7
Y+ Kenya: supporting young people living with HIV	7
HIV epidemiology in the WHO Eastern Mediterranean region: a multicountry programme review	7
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administere	7
Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial	7
Hungary's new LGBTQI legislation could harm HIV response	7
Closeted life of a Hollywood giant	7
Protease inhibitor-based antiretroviral therapy in pregnancy: effects on hormones, placenta, and decidua	7
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-	7
From early alarm to gradual control of monkeypox	7
Documenting the UK's 40-year battle with HIV/AIDS	7